Morgan Stanley analyst Michael Ulz assumed coverage of Rhythm Pharmaceuticals (RYTM) with an Overweight rating and $72 price target The firm expects positive Phase 3 setmelanotide data in hypothalamic obesity in Q2 to drive “meaningful upside,” while next generation programs have the potential to further improve the profile, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential
- Promising Market Potential for Rhythm Pharmaceuticals’ Setmelanotide in Treating Hypothalamic Obesity
- Rhythm Pharmaceuticals resumed with a Buy at Stifel
- Promising Clinical Milestones and Strong Financial Outlook Reinforce Buy Rating for Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals price target raised to $70 from $69 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com